spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:

Advertising

David Hirsh


 

Editorial 

Emma Naks
  

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.



View the
digital version
of EBR


ebr
 
 
Featured in this issue
BIOIMAGING
Drug Development

Eye for Success


MPI Research’s Scott Haller believes that contemporary molecular imaging offers pharma a set of tools capable of dramatically de-risking clinical drug development.
BioDevelopment
Q&A: Cell Line Development

Path to Progress


FUJIFILM Diosynth Biotechnologies’ Alison Porter tells EBR what must be considered when creating a new host cell line, and gives tips on how to save future development time and meet production requirements.



  Legal, Regulatory and Public Policy
Regulatory Challenge

Rapid response


The growing advances in genomics and how this area fi ts in with personalised medicine is uncharted territory, particularly for regulatory agencies. Regina Au at BioMarketing Insight contemplates the current approval processes.


spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

Banner of Ionicon.EBR on Samedan
 
Industry Events

RNA Therapeutics

16-17 February 2015, London, United Kingdom

RNA Therapeutics 2015 returns to London on 16th and 17thFebruary, gathering a room full of scientific pioneers and industry experts to identify the latest advancements, best practice and strategies to maximise return on investment.
More info >>

 
News and Press Releases

New Methodology Offers Earlier Cardiac Safety Characterisation and Significant Cost Savings

On 12 December 2014, the FDA hosted a full day Cardiac Safety Research Consortium (CSRC) meeting to release the results of the IQ-CSRC Study, demonstrating the ability to conduct robust cardiac safety characterisation several years earlier than current practice in clinical development.
More info >>

air transport logo

 

White Papers

Unmet Medical Needs? Impacted by unmet Life Sciences Staffing Needs?

Clinical Professionals

Whilst the majority of Clinical Professionals clients are working to discover and develop innovative, cost effective medicines that address unmet medical needs they are not impacting the unmet needs of training and developing new recruits into the pharma industry. The impact is highlighted within entry level Clinical Trial Administrators and Clinical Research Associates (CTA/CRA). In the past the Pharmaceutical industry had highly developed training programs for these sought after candidates. As the use of outsourcing models and CRO’s has increased and fewer Pharma businesses embark on their own R&D a substantial gap is developing in newly trained Life Science graduates entering the market to commence a career within R&D. As further financial cuts are made within R&D spend this already dire situation continues to escalate.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement